NCT06524245 A Predictive Model for Recurrence of Colorectal Cancer Based on Multi-omics of Portal Vein Blood
| NCT ID | NCT06524245 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Shougang Hospital |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2020-01-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2020-01-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This multi-center study aims to develop a precise predictive model for colorectal cancer (CRC) recurrence and metastasis based on multi-omics analysis of portal vein blood. Despite advances in surgical treatments, approximately 40% of CRC patients experience tumor recurrence or metastasis post-surgery, with 80-90% of metastases being unresectable. The study will include stage I-IV CRC patients and will be conducted in two phases: a nested case-control study and a bidirectional cohort study. Comprehensive multi-omics sequencing will be performed on samples from primary tumors, adjacent tissues, normal intestinal tissues, portal vein blood, and peripheral blood. The goal is to identify specific biomarkers in the portal vein and peripheral blood associated with CRC recurrence and metastasis, and to compare the predictive accuracy of models based on these biomarkers. The ultimate objective is to provide a more effective method for early prediction and intervention of CRC recurrence and metastasis, thereby improving patient outcomes. Project Information: Project Title: A predictive model for recurrence of colorectal cancer based on multi-omics of portal vein blood: a multi-center study Project Duration: January 2020 to December 2026 Lead Institution: Peking University Shougang Hospital Principal Investigator: Gu Jin Contact: Hong Haopeng, 18059211195@163.com
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Histologically confirmed stage I-IV colorectal cancer (CRC) * Availability of pre-operative and intra-operative blood samples (portal vein and peripheral blood) and primary tumor tissue samples * No neoadjuvant therapy before surgery Exclusion Criteria: * Prior history of other malignancies * Incomplete clinical information or pathology reports * Incomplete follow-up records
Contact & Investigator
Jin Gu, Prof.
PRINCIPAL INVESTIGATOR
Peking University Shougang Hospital
Frequently Asked Questions
Who can join the NCT06524245 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06524245 currently recruiting?
Yes, NCT06524245 is actively recruiting participants. Contact the research team at hdn1208@163.com for enrollment information.
Where is the NCT06524245 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06524245 clinical trial?
NCT06524245 is sponsored by Peking University Shougang Hospital. The principal investigator is Jin Gu, Prof. at Peking University Shougang Hospital. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.